Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
Provided By GlobeNewswire
Last update: Jun 25, 2024
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing
Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA
Read more at globenewswire.com
